Ou, S-H.I. : rechercher sur Z-Library

Le plus grand référentiel d'articles scientifiques au monde. 70,000,000+ d'articles gratuitement.

Don't use scam websites

Livres
Articles (29)
Les plus populaires
Liste
- Liste
- Tableau

1

Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma

Shen, Y-C, Ou, D-L, Hsu, C, Lin, K-L, Chang, C-Y, Lin, C-Y, Liu, S-H, Cheng, A-L

Journal:

British Journal of Cancer

Année:

2013

Langue:

english

Fichier:

PDF, 1.76 MB

english, 2013

2

Epidemiology of nasopharyngeal carcinoma in the United States: improved survival of Chinese patients within the keratinizing squamous cell carcinoma histology

Ou, S-H., Zell, J., Ziogas, A, Anton-Culver, H

Journal:

Annals of Oncology

Année:

2006

Langue:

english

Fichier:

PDF, 168 KB

english, 2006

3

Positive regulation of β-catenin–PROX1 signaling axis by DBC1 in colon cancer progression

Yu, E J, Kim, S-H, Kim, H J, Heo, K, Ou, C-Y, Stallcup, M R, Kim, J H

Journal:

Année:

2015

Langue:

english

Fichier:

PDF, 2.12 MB

english, 2015

4

Increased risk of pulmonary tuberculosis in patients with gastroesophageal reflux disease

Fan, W-C., Ou, S-M., Feng, J-Y., Hu, Y-W., Yeh, C-M., Su, V. Y-F., Hu, L-Y., Chien, S-H., Su, W-J., Chen, T-J., Liu, C-J.

Journal:

The International Journal of Tuberculosis and Lung Disease

Année:

2016

Langue:

english

Fichier:

PDF, 222 KB

english, 2016

5

Natural History of Stage I Non-Small Cell Lung Cancer

Raz, Dan J., Zell, Jason A., Ou, S-H. Ignatius, Gandara, David R., Anton-Culver, Hoda, Jablons, David M.

Journal:

Année:

2007

Langue:

english

Fichier:

PDF, 300 KB

english, 2007

6

HER2 V659 and G660 transmembrane mutations that stabilize homo- and hetero-dimerization are rare oncogenic drivers in lung adenocarcinoma that are clinically responsive to afatinib

Ou, S-H.I., Schrock, A.B., Bocharov, E.V., Klempner, S.J., Haddad, C.K., Steinecker, G., Johnson, M., Gitlitz, B., Chung, J., Campregher, P., Ross, J.S., Stephens, P.J., Miller, V.A., Suh, J., Ali, S.

Journal:

Annals of Oncology

Année:

2016

Langue:

english

Fichier:

PDF, 40 KB

english, 2016

7

Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): updated results from PROFILE 1001

Shaw, A., Riley, G.J., Bang, Y-J., Kim, D-W., Camidge, D.R., Varella-Garcia, M., Lafrate, A.J., Shapiro, G., Winter, M., Usari, T., Wang, S.C., Wilner, K., Clark, J.W., Ou, S-H.I.

Journal:

Annals of Oncology

Année:

2016

Langue:

english

Fichier:

PDF, 37 KB

english, 2016

8

Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC)

Antonia, S.J., Brahmer, J.R., Khleif, S., Balmanoukian, A.S., Ou, S-H.I., Gutierrez, M., Kim, D-W., Kim, S-W., Ahn, M-J., Leach, J., Jamal, R., Jaeger, D., Jerusalem, G., Jin, X., Gupta, A., Antal, J.

Journal:

Annals of Oncology

Année:

2016

Langue:

english

Fichier:

PDF, 49 KB

english, 2016

9

Updated safety and efficacy of durvalumab (MEDI4736), an anti-PD-L 1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort

Segal, N.H., Ou, S-H.I., Balmanoukian, A.S., Massarelli, E., Brahmer, J.R., Weiss, J., Schoffski, P., Antonia, S.J., Massard, C., Zandberg, D.P., Maher, C., Khleif, S., Jin, X., Rebelatto, M., Steele,

Journal:

Annals of Oncology

Année:

2016

Langue:

english

Fichier:

PDF, 43 KB

english, 2016

10

Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK+ non-small-cell lung cancer (NSCLC)

Barlesi, F., Dingemans, A-M.C., Yang, J.C-H., Ou, S-H.I., Ahn, J.S., De Petris, L., Hughes, B., Lena, H., Bordogna, W., Golding, S., Morcos, P.N., Balas, B., Zeaiter, A., Kim, D-W.

Journal:

Annals of Oncology

Année:

2016

Langue:

english

Fichier:

PDF, 47 KB

english, 2016

11

Rociletinib-associated cataracts in EGFR-mutant NSCLC

Piotrowska, Z., Liu, E., Varga, A., Thakur, M., Narayanan, V., Liu, S.V., Neal, J., Spiegel, M., Solomon, B., Yu, H., Ou, S-H.I., Papadimitrakopoulou, V.A., Gadgeel, S., Camidge, D.R., Soria, J-C., Wa

Journal:

Annals of Oncology

Année:

2016

Langue:

english

Fichier:

PDF, 41 KB

english, 2016

12

1343PEfficacy and safety of lorlatinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) previously treated with 2nd-generation ALK TKIs

Felip Font, E., Shaw, A.T., Solomon, B.J., Bauer, T.M., Ou, S-H.I., Gadgeel, S., Soo, R.A., Seto, T., Clancy, J.S., James, L.P., Abbattista, A., Besse, B.

Journal:

Annals of Oncology

Année:

2017

Langue:

english

Fichier:

PDF, 83 KB

english, 2017

13

1633PDCo-amplification of KIT/KDR/PDGRA in over 100,000 advanced cancer cases

Disel, U., Madison, R., Chung, J., Gounder, M., Oztan, A., Benson, A., Webster, J., Klempner, S.J., Ou, S-H.I., Ganesan, S., Janeway, K., Stephens, P.J., Ross, J.S., Schrock, A.B., Miller, V.A., Ali,

Journal:

Annals of Oncology

Année:

2017

Langue:

english

Fichier:

PDF, 67 KB

english, 2017

14

410O_PRAlectinib (ALC) vs crizotinib (CRZ) in treatment-naïve ALK+ non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study

Mok, T S K, Peters, S, Camidge, D R, Ou, S-H I, Ahn, J S, Tan, E H, Li, Z, Lee, J-S, Cho, B C, Geater, S L, Sriuranpong, V, Ho, J, Chan, O S-H, Zeaiter, A, Balas, B, Nueesch, E, Mitry, E, Morcos, P N,

Journal:

Annals of Oncology

Année:

2017

Langue:

english

Fichier:

PDF, 72 KB

english, 2017

15

87OBrigatinib in ALK+ NSCLC pts with intracranial CNS metastases in 2 clinical trials

Tiseo, M., Huber, R.M., Hochmair, M.J., Bazhenova, L.A., Ou, S-H.I., Reichmann, W., Haney, J., Kerstein, D., Camidge, D.R., Gettinger, S.N.

Journal:

Annals of Oncology

Année:

2017

Langue:

english

Fichier:

PDF, 52 KB

english, 2017

16

Lung sarcomatoid carcinoma (LSC) harbors targetable genomic alterations and high mutational burden as observed by comprehensive genomic profiling (CGP)

Halmos, B., Frampton, G.M., Suh, J., Braun, E., Mehra, R., Buck, S., Bufill, J.A., Peled, N., Karim, N.A., Fishkin, P., Knost, J., Ou, S-H.I., Ross, J.S., Stephens, P.J., Miller, V.A., Ali, S.M., Schr

Journal:

Annals of Oncology

Année:

2016

Langue:

english

Fichier:

PDF, 37 KB

english, 2016

17

1345PIntracranial efficacy of brigatinib (BRG) in patients (Pts) With crizotinib (CRZ)-refractory anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) and baseline CNS metastases

Ou, S-H.I., Tiseo, M., Camidge, R., Ahn, M-J., Huber, R.M., Hochmair, M.J., Kim, S-W., West, H.L., Reckamp, K.L., Molina, J.R., Liu, G., Delmonte, A., Viteri, S., Bearz, A., Summers, Y., Reichmann, W.

Journal:

Annals of Oncology

Année:

2017

Langue:

english

Fichier:

PDF, 63 KB

english, 2017

18

1OComprehensive Genomic Profiling (CGP) of 114,200 advanced cancers identifies recurrent Kinase Domain Duplications (KDD) and novel oncogenic fusions in diverse tumor types

Ikeda, S, Gay, L, Pavlick, D, Chung, J, Ramkissoon, S, Daniel, S, Elvin, J, Severson, E, Bivona, T, Reckamp, K, Klempner, S, Ou, S-H I, Schrock, A, Miller, V, Stephens, P, Ross, J, Ganesan, S, Lovly,

Journal:

Annals of Oncology

Année:

2017

Langue:

english

Fichier:

PDF, 64 KB

english, 2017

19

1700OGenomic profiling of 114,200 advanced cancers identifies recurrent kinase domain duplications (KDD) and oncogenic rearrangements (RE) across diverse tumor types

Gay, L.M., Pavlick, D., Chung, J., Ramkissoon, S., Daniel, S., Elvin, J.A., Severson, E., Bivona, T., Reckamp, K.L., Klempner, S.J., Ou, S-H.I., Schrock, A.B., Miller, V.A., Stephens, P.J., Ross, J.S.

Journal:

Annals of Oncology

Année:

2017

Langue:

english

Fichier:

PDF, 95 KB

english, 2017

20

158P Afatinib in patients with EGFR mutation-positive (EGFRm+) NSCLC harbouring uncommon mutations: Overview of clinical data

Märten, A., Yamamoto, N., Yu, C-J., Ou, S-H.I., Zhou, C., Wu, Y-L.

Journal:

Journal of Thoracic Oncology

Année:

2018

Langue:

english

Fichier:

PDF, 79 KB

english, 2018

21

Pediatric, adolescent and young adult (PAYA) thyroid carcinoma harbors frequent and diverse targetable genomic alterations including kinase fusions

Borre, P. Vanden, Schrock, A.B., Anderson, P., Heilmann, A.M., Holmes, O., Wang, K., Khan, S., Morris, J.C., Ou, S-H.I., Waguespack, S., Stephens, P., Erlich, R.L., Miller, V., Ross, J.S., Ali, S.

Journal:

Annals of Oncology

Année:

2016

Langue:

english

Fichier:

PDF, 65 KB

english, 2016

22

1298O_PRAlectinib vs crizotinib in treatment-naïve ALK+ NSCLC: CNS efficacy results from the ALEX study

Gadgeel, S., Peters, S., Mok, T.S.K., Shaw, A.T., Kim, D-W., Ou, S-H.I., Perol, M., Dziadziuszko, R., Ahn, J.S., Rosell, R., Zeaiter, A., Mitry, E., Nueesch, E., Balas, B., Camidge, R.

Journal:

Annals of Oncology

Année:

2017

Langue:

english

Fichier:

PDF, 107 KB

english, 2017

23

Time to response in patients with ALK+ NSCLC receiving alectinib in the phase II NP28673 and NP28761 studies

Gandhi, L., Gadgeel, S., Shaw, A., Barlesi, F., Crinò, L., Yang, J.C-H., Dingemans, A-M.C., Kim, D-W., de Marinis, F., Schulz, M., Liu, S., Fish, S., Kotb, A., Ou, S-H.I.

Journal:

Annals of Oncology

Année:

2016

Langue:

english

Fichier:

PDF, 74 KB

english, 2016

24

107OCrizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): Overall survival (OS) and updated safety from PROFILE 1001

Shaw, A, Riely, G J, Bang, Y-J, Kim, D-W, Camidge, D R, Shapiro, G I, Usari, T, Wang, S C, Wilner, K, Clark, J W, Ou, S-H I

Journal:

Annals of Oncology

Année:

2019

Langue:

english

Fichier:

PDF, 91 KB

english, 2019

25

1397PLong-term safety of crizotinib in previously treated patients (pts) with ALK-positive advanced/metastatic non-small cell lung cancer (NSCLC)

Crinò, L, Ahn, M-J, Han, J-Y, Liu, X, Ou, S-H I, Shaw, A T, Yang, P-C, Shi, Y-K, Lanzalone, S, Polli, A, Wilner, K D, Kim, D-W

Journal:

Annals of Oncology

Année:

2018

Fichier:

PDF, 90 KB

2018

26

1484PDFinal PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC

Mok, T S K, Shaw, A T, Camidge, R D, Gadgeel, S M, Rosell, R, Dziadziuszko, R, Kim, D-W, Perol, M, Ou, S-H, Bordogna, W, Smoljanović, V, Hilton, M, Peters, S

Journal:

Annals of Oncology

Année:

2019

Fichier:

PDF, 96 KB

2019

27

Pan-tumor characterization of KRAS mutations (KRASm) detected in circulating tumor DNA (ctDNA) and concordance with paired tissue

Lee, J., Chung, J.H., Venstrom, J., Alexander, B., Schrock, A.B., Ou, S-H.I.

Journal:

Annals of Oncology

Année:

2020

Fichier:

PDF, 94 KB

2020

28

Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy

Liu, S.V., De Braud, F., Drilon, A., Doebele, R.C., Patel, M.R., Cho, B.C., Ahn, M-J., Chiu, C-H., Farago, A.F., Goto, K., Lee, J., Ohe, Y., Ou, S-H.I., Cassier, P., Tan, D.S.W., Otterson, G.A., Veron

Journal:

Annals of Oncology

Année:

2020

Fichier:

PDF, 114 KB

2020

29

539P Patient-reported outcomes (PROs) from patients (Pts) with NTRK fusion-positive (NTRK-fp) solid tumours receiving entrectinib in the global phase II STARTRK-2 study

Conley, A.P., Demetri, G.D., Doebele, R.C., Drilon, A., Paz-Ares, L., Cassier, P., Siena, S., Ahn, M-J., Buchschacher, G.L., Seto, T., Chee, C.E., Krzakowski, M., Ou, S-H.I., GrohÃ©, C., Zagonel, V.,

Journal:

Annals of Oncology

Année:

2020

Fichier:

PDF, 131 KB

2020